Literature DB >> 18199633

Unanswered questions in schizophrenia clinical trials.

John M Kane1, Stefan Leucht.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18199633      PMCID： PMC2632396          DOI： 10.1093/schbul/sbm143

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  50 in total

1.  Early prediction of antipsychotic response in schizophrenia.

Authors:  Christoph U Correll; Anil K Malhotra; Saurabh Kaushik; Marjorie McMeniman; John M Kane
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

Review 2.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

3.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

Authors:  D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 5.  Sleep disturbance in schizophrenia.

Authors:  Jaime M Monti; Daniel Monti
Journal:  Int Rev Psychiatry       Date:  2005-08

6.  Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.

Authors:  G E Hogarty; N R Schooler; R Ulrich; F Mussare; P Ferro; E Herron
Journal:  Arch Gen Psychiatry       Date:  1979-11

Review 7.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

8.  Predicting outcome of antipsychotic drug treatment from early response.

Authors:  P R May; T Van Putten; C Yale
Journal:  Am J Psychiatry       Date:  1980-09       Impact factor: 18.112

Review 9.  Lithium for schizophrenia.

Authors:  S Leucht; W Kissling; J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

10.  Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112
View more
  8 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

3.  Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

4.  Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

Authors:  Eric Y H Chen; Christy L M Hui; May M L Lam; Cindy P Y Chiu; C W Law; Dicky W S Chung; Steve Tso; Edwin P F Pang; K T Chan; Y C Wong; Flora Y M Mo; Kathy P M Chan; T J Yao; S F Hung; William G Honer
Journal:  BMJ       Date:  2010-08-19

5.  Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.

Authors:  Holland C Detke; Fangyi Zhao; Michael M Witte
Journal:  BMC Psychiatry       Date:  2012-05-30       Impact factor: 3.630

Review 6.  Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives.

Authors:  Christoph U Correll; Taishiro Kishimoto; John M Kane
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 7.  Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia.

Authors:  Kotaro Hatta; Hiroto Ito
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-04-24       Impact factor: 2.582

8.  Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection.

Authors:  Christian Asseburg; Michael Willis; Mickael Löthgren; Niko Seppälä; Mika Hakala; Ulf Persson
Journal:  Schizophr Res Treatment       Date:  2012-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.